Efficacy and safety of transdermal testosterone in postmenopausal women with hypoactive sexual desire disorder: a systematic review and meta-analysis

Achilli, Chiara; Pundir, Jyotsna; Ramanathan, Parimalam; Sabatini, Luca; Hamoda, Haitham; Panay, Nick

doi:10.1016/j.fertnstert.2016.10.028

Cited by 115 publications

(75 citation statements)

References 51 publications

(94 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…A recent meta‐analysis of 7 randomized controlled trials (N = 3035) of a transdermal testosterone patch in women who were naturally or surgically postmenopause and had a diagnosis of hypoactive sexual desire disorder concluded that women using testosterone had significantly more satisfying sexual experiences (including sexual activity, orgasm, and desire) than women using placebo. The meta‐analysis did not find any significant increase in adverse events, although there were increases in acne, hair growth, and site reactions . There is no current testosterone formulation specifically for women.…”

Section: Systemic Hormone Therapy For Menopause‐related Symptomsmentioning

confidence: 87%

See 1 more Smart Citation

An Update on Menopause Management

Ward¹,

Deneris²

2018

J Midwife Womens Health

View full text Add to dashboard Cite

Menopause-related symptoms frequently lead women to seek health care. Recommendations for prescribing hormone therapy have changed significantly since the publication of initial results from the Women's Health Initiative (WHI) study in 2002. The North American Menopause Society and the American College of Obstetricians and Gynecologists have newer guidelines based on long-term analyses of the WHI participants as well as emerging data from other clinical trials. Women with an intact uterus who are using systemic estrogen must also use a progestogen; however, there are 2 new selective estrogen receptor modulators on the market for use without a progestogen. This review discusses current recommendations and new medications as well as the risks and benefits related to hormone therapy. Evidence-based alternatives to hormone therapy to treat symptoms of menopause are also presented.

show abstract

Section: Systemic Hormone Therapy For Menopause‐related Symptomsmentioning

confidence: 87%

“…The meta-analysis did not find any significant increase in adverse events, although there were increases in acne, hair growth, and site reactions. 32 There is no current testosterone formulation specifically for women.…”

Section: Testosteronementioning

confidence: 99%

An Update on Menopause Management

Ward¹,

Deneris²

2018

J Midwife Womens Health

View full text Add to dashboard Cite

show abstract

“…These include lifestyle and dietary modifications, supplements, mind–body techniques, and cooling methods (Table ) . The short‐term efficacy of topical treatment such as transdermal testosterone at improving female SD has been reported without any serious adverse events . However, study participants did not have preexisting liver disease or cirrhosis.…”

Section: Management Of Sd and Reproductive Dysfunction In Patients Wimentioning

confidence: 96%

Sexual Dysfunction and Sex Hormone Abnormalities in Patients With Cirrhosis: Review of Pathogenesis and Management

2019

View full text Add to dashboard Cite

Healthy sexual function is important to maintain a good quality of life but is frequently impaired in patients with cirrhosis. The degree of sexual dysfunction appears to be linked with the degree of hepatic dysfunction. In men, sexual dysfunction can be related to the hyperestrogenism of portal hypertension and/or to decreased testosterone resulting from testicular dysfunction. In women, suppression of the hypothalamic–pituitary–gonadal axis appears to be a principal contributor, with no significant effect of portal hypertension. There is also a huge psychological barrier to break through as there is a component of depression in many patients with cirrhosis. Sexual dysfunction is often underdiagnosed in the cohort with cirrhosis. Management of sexual disorders in patients with cirrhosis can be challenging as they are often multifactorial. A multidisciplinary approach is key in managing these patients. We review the current literature on the pathogenesis of sexual dysfunction in patients with cirrhosis and propose a stepwise algorithm to better manage these patients.

show abstract

“…Recommendations regarding systemic testosterone therapy for postmenopausal women, in doses that approximate physiological testosterone concentrations for premenopausal women, based on findings from meta-analyses of placebo/comparator-controlled randomized clinical trials [1,16] There are insufficient data to make any recommendations regarding the use of testosterone in premenopausal women for treatment of sexual function or any other outcome (Insufficient).…”

Section: 2mentioning

confidence: 99%